» Articles » PMID: 33134907

Epigenetics in Hepatocellular Carcinoma Development and Therapy: The Tip of the Iceberg

Overview
Journal JHEP Rep
Specialty Gastroenterology
Date 2020 Nov 2
PMID 33134907
Citations 59
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinoma (HCC) is a deadly tumour whose causative agents are generally well known, but whose pathogenesis remains poorly understood. Nevertheless, key genetic alterations are emerging from a heterogeneous molecular landscape, providing information on the tumorigenic process from initiation to progression. Among these molecular alterations, those that affect epigenetic processes are increasingly recognised as contributing to carcinogenesis from preneoplastic stages. The epigenetic machinery regulates gene expression through intertwined and partially characterised circuits involving chromatin remodelers, covalent DNA and histone modifications, and dedicated proteins reading these modifications. In this review, we summarise recent findings on HCC epigenetics, focusing mainly on changes in DNA and histone modifications and their carcinogenic implications. We also discuss the potential drugs that target epigenetic mechanisms for HCC treatment, either alone or in combination with current therapies, including immunotherapies.

Citing Articles

Epigenetic modifications in early stage lung cancer: pathogenesis, biomarkers, and early diagnosis.

Bi L, Wang X, Li J, Li W, Wang Z MedComm (2020). 2025; 6(3):e70080.

PMID: 39991629 PMC: 11843169. DOI: 10.1002/mco2.70080.


Epigenetic regulation and its therapeutic potential in hepatitis B virus covalently closed circular DNA.

Ren J, Cheng S, Ren F, Gu H, Wu D, Yao X Genes Dis. 2024; 12(1):101215.

PMID: 39534573 PMC: 11555349. DOI: 10.1016/j.gendis.2024.101215.


Integration of epigenomic and transcriptomic profiling uncovers EZH2 target genes linked to cysteine metabolism in hepatocellular carcinoma.

Lee J, You C, Kwon G, Noh J, Lee K, Kim K Cell Death Dis. 2024; 15(11):801.

PMID: 39516467 PMC: 11549485. DOI: 10.1038/s41419-024-07198-0.


Deciphering the multifaceted role of microRNAs in hepatocellular carcinoma: Integrating literature review and bioinformatics analysis for therapeutic insights.

Rahdan F, Saberi A, Saraygord-Afshari N, Hadizadeh M, Fayeghi T, Ghanbari E Heliyon. 2024; 10(20):e39489.

PMID: 39498055 PMC: 11532857. DOI: 10.1016/j.heliyon.2024.e39489.


Mitoepigenetics pathways and natural compounds: a dual approach to combatting hepatocellular carcinoma.

Hatawsh A, Al-Haddad R, Okafor U, Diab L, Dekanoidze N, Abdulwahab A Med Oncol. 2024; 41(12):302.

PMID: 39465473 DOI: 10.1007/s12032-024-02538-8.


References
1.
Hyun K, Jeon J, Park K, Kim J . Writing, erasing and reading histone lysine methylations. Exp Mol Med. 2017; 49(4):e324. PMC: 6130214. DOI: 10.1038/emm.2017.11. View

2.
Bubna A . Vorinostat-An Overview. Indian J Dermatol. 2015; 60(4):419. PMC: 4533557. DOI: 10.4103/0019-5154.160511. View

3.
Macchi F, Sadler K . Unraveling the Epigenetic Basis of Liver Development, Regeneration and Disease. Trends Genet. 2020; 36(8):587-597. DOI: 10.1016/j.tig.2020.05.002. View

4.
Cleary S, Jeck W, Zhao X, Chen K, Selitsky S, Savich G . Identification of driver genes in hepatocellular carcinoma by exome sequencing. Hepatology. 2013; 58(5):1693-702. PMC: 3830584. DOI: 10.1002/hep.26540. View

5.
Kuang Y, El-Khoueiry A, Taverna P, Ljungman M, Neamati N . Guadecitabine (SGI-110) priming sensitizes hepatocellular carcinoma cells to oxaliplatin. Mol Oncol. 2015; 9(9):1799-814. PMC: 5528722. DOI: 10.1016/j.molonc.2015.06.002. View